You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Biogen drug shows signs of promise

NEW YORK — Biogen Idec Inc. said Thursday its longer-lasting injectable multiple sclerosis drug, peginterferon beta-1a, helped reduce patients’ risk of relapse by 36 percent when given every two weeks, meeting the goals of a late-stage study.

The medicine reduced patients’ risk of flare-ups by 28 percent when dosed every four weeks compared with placebo, the Weston, Mass., firm said in a statement. Based on the results, Biogen said it plans to apply this year for regulatory approval in Europe and the United States.

Continue reading below

Peginterferon is a version of Biogen’s best-selling drug, Avonex, which is given by injection once a week. Avonex generated $2.7 billion in 2011 revenue. The longer-lasting drug would be deemed successful if it reduced the risk of relapse by at least 30 percent, said Michael Yee, an analyst with RBC Capital Markets.

The trial of more than 1,500 patients was part of the third and final stage of studies generally required for US approval. The drug was safe and tolerable across different dosing frequencies, Biogen said. The most common side effects were redness at the injection site and flu-like symptoms.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of